Search

everythinglearnresearchcommunity

for

Search:↓

User shares 3-month progress with Big3 treatment (finasteride 0.15mg, minox twice a day, 0.75mm microneedling weekly). Others discuss results, dosage, and potential benefits of higher finasteride dose.

A female user in her mid-20s with androgenetic alopecia and suspected telogene effluvium who has been taking Dutasteride, Spironolactone, Minoxidil, Dermarolling, Ketoconazol shampoo, and Yaz contraception for her hair loss for the past 6 months. She had a small shed during this time that she believes to be stress related.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

The user stopped using finasteride and RU58841 and is considering CB-03-01 for androgenic alopecia but is concerned about the cost and effectiveness, especially at a lower dose than in clinical trials. They are also using minoxidil, micro-needling, and nizoral shampoo but are unsure about the correct application method for CB-03-01.

User on fin, minox, and ketoconazole seeks to add another topical anti-androgen. Hierarchy of effectiveness: 1. RU55841, 2. Fluridil - Eucapil, 3. CB-03-01 - Breezula, 4. Ketoconazole; alfatradiol suggested as addition.

The user underwent a DHI hair transplant with 3,066 grafts at Hairtec in the Netherlands and is using finasteride and minoxidil to restore hair, particularly at the crown. They plan to adjust minoxidil dosage and consult with a dermatologist in September.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.

The conversation discusses Kintor's initiation of a new Phase 3 trial to assess the long-term safety of Pyrilutamide (KX-826) for hair loss, which will last 52 weeks. Specific treatments mentioned include Pyrilutamide.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.

A user is seeking hair loss treatments without using systemic DHT blockers like finasteride due to side effects. Suggestions include clascoterone (not FDA approved), pyrilutamide, RU58841, and low-dose topical finasteride, with a recommendation to consult a doctor.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

Hair loss treatments RU55841, CB-03-01, and Eucapil were discussed, with concerns about needing increased dosages over time and potential side effects. A user suggested that CB's results could be due to various factors and that combining it with finasteride might slow down any upregulation.

A user's progress with treating their hair loss, which consists of using Dutasteride, RU58841, Stemoxydine and Tretinoin 0.05% over the past three months.

The conversation is about someone's 13-month hair regrowth progress using 0.5 mg Dutasteride daily, 5% Minoxidil twice daily, Biotin tablets, and Sebizole shampoo. They are happy with the results.

Corticosterone inhibits GAS6, affecting hair follicle stem-cell activity, with potential implications for stress-related hair loss. Ashwagandha and Vitamin K are suggested for reducing cortisol, but their effectiveness is debated.

RU58841 helped regrow hairline without side effects for a bodybuilder using PEDs. The treatment included RU58841, finasteride, minoxidil, GKH-Cu, microneedling, and HGH.

Clascoterone is being discussed for hair loss, but its current acne formulation may not be suitable for scalp use due to potential skin irritation and lower dosage compared to Breezula. Users mention other treatments like finasteride, minoxidil, and pyrilutamide, with some expressing skepticism about clascoterone's effectiveness for hair loss.

Hair regrowth treatment involving 3aHSD enzyme shows 6% improvement in 18 weeks. Sulforaphane, L-Menthol, and Dexpanthenol are potential ingredients for new hair loss solution.

Hair loss treatments discussed include cosmeRNA, minoxidil, finasteride, RU58841, and pyrilutamide. Users debate effectiveness, side effects, and upcoming treatments, with some expressing skepticism and others optimism.

RU58841 is discussed as a hair loss treatment, with users considering lower doses like 2.5% to reduce costs. Some users suggest that if already blocking DHT, lower doses might still be effective unless there's high sensitivity to DHT.

Winlevi (clascoterone) is discussed as a treatment for hormonal acne and seborrheic dermatitis due to its ability to block DHT and regulate sebum production. The post suggests that Winlevi could offer a novel approach for managing seborrheic dermatitis.

Clascoterone 5% solution (Breezula) is a promising alternative for androgenetic alopecia, showing continued hair growth with consistent use and no significant side effects. It may be suitable for those who cannot tolerate finasteride or dutasteride, especially when trying to conceive.

Increased hair loss after starting a 10g daily creatine regimen, possibly linked to elevated DHT levels despite dutasteride use. Stopping creatine reduced shedding, but the exact cause is uncertain, with discussions on exercise and lifestyle impacts.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

The post and conversation are about a user's 3-month progress using Minoxidil, Finasteride, Nizoral shampoo, and derma-rolling for hair loss. The user reports noticeable improvement in their hairline.

Bicalutamide blocks androgen receptors, preventing testosterone and DHT from binding, which can help with hair loss but may cause feminization. It is not recommended for those who do not want feminization effects.

Using topical finasteride with creatine might help reduce hair loss by targeting local DHT while maintaining normal systemic levels, but results are uncertain without testing. Users report mixed experiences with topical treatments like finasteride, dutasteride, RU58841, and minoxidil, with some seeing regrowth and others experiencing side effects.

A user's experience using dutasteride, minoxidil, ketoconazole, vitamin D, scalp massage, exercise, and avoiding vaping and 2-in-1 shampoo/conditioner to treat hair loss; they also discussed the side effects of finasteride.

Clascoterone is being discussed as a promising new hair loss treatment, showing significant improvement in trials. Despite this, skepticism persists about its effectiveness, cost, and side effects, with some users preferring minoxidil and finasteride.